The xamoterol experience in the treatment of heart failure

The American Journal of Cardiology
J M Cruickshank

Abstract

Beta blockers may benefit patients with dilated cardiomyopathy but low output failure can be a problem. Thus a beta 1-selective beta blocker with about 45% intrinsic sympathomimetic activity (ISA), such as xamoterol, was thought to have a desirable pharmacologic profile. Long-term studies of xamoterol in patients with idiopathic dilated cardiomyopathy have shown improved cardiac performance and exercise tolerance, while exercise heart rate, left ventricular ejection fraction, and pulmonary artery wedge pressure were decreased. This improvement in exercise capacity and overall quality of life in patients treated with xamoterol has been confirmed in further controlled trials of patients with mild-to-moderate heart failure (NYHA class I and II). However, in patients with moderate-to-severe heart failure (NYHA class III and IV), mortality was unfavorably influenced by xamoterol. The therapeutic role of xamoterol in patients with heart disease needs further refinement.

References

Oct 1, 1975·British Heart Journal·F WaagsteinI Wallentin
Apr 1, 1990·European Heart Journal·R M TimewellH F Marlow
Feb 1, 1985·The American Journal of Cardiology·J L AndersonM Bartholomew
Jan 1, 1986·European Journal of Clinical Pharmacology·L BarriosH de Geest
Jan 1, 1988·European Journal of Clinical Pharmacology·E V SorensenW Bastain
Sep 1, 1966·The American Journal of Cardiology·S A Stephen
Aug 1, 1980·British Heart Journal·K SwedbergI Wallentin
Mar 1, 1981·American Heart Journal·M BrezisJ Hasin
Aug 7, 1965·British Medical Journal·P M GILLAM, B N PRICHARD

❮ Previous
Next ❯

Citations

Sep 5, 2001·International Journal of Cardiology·D J van Veldhuisen, P A Poole-Wilson
Oct 9, 2002·Congestive Heart Failure·Denise D Hermann
Jan 1, 1997·Journal of Clinical Pharmacology·T W Hash, L M Prisant
May 29, 2008·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Jeffrey K Aronson
Jul 10, 2002·Journal of the American College of Cardiology·Harold L Kennedy, Robert S Rosenson
Dec 1, 1993·Circulation·P W Armstrong, G W Moe
May 22, 2002·Circulation·Peter AndrekaNanette H Bishopric
Apr 1, 1995·Cardiovascular Drugs and Therapy·V PanfilovG Olsson
Aug 16, 2005·International Journal of Cardiology·Sergio V Perrone, Edgardo J Kaplinsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.